EP0845983A2 - Pharmaceutical composition with trypanocidal properties - Google Patents
Pharmaceutical composition with trypanocidal propertiesInfo
- Publication number
- EP0845983A2 EP0845983A2 EP96929285A EP96929285A EP0845983A2 EP 0845983 A2 EP0845983 A2 EP 0845983A2 EP 96929285 A EP96929285 A EP 96929285A EP 96929285 A EP96929285 A EP 96929285A EP 0845983 A2 EP0845983 A2 EP 0845983A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical preparation
- preparation according
- water
- weight
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
Definitions
- the invention relates to a pharmaceutical preparation with trypanozid properties for the veterinary field, in the form of an aqueous solution, the diminazenediacetate (4,4'-diamidinodiazobenzenediacetamidoacetate) and pentamidine (4,4 '- (pentamethylendioxy) ) -dibenzamidine) as trypanozide active ingredients, phenazone (1,2-dihydro-l, 5-dimethyl-2-phenyl-3H-pyrazol-3-one) as antipyretic and analgesic component as well as glycerin.
- Arsenic preparations and trypan dyes are known as chemotherapeutic agents, but due to their arsenic
- a preparation for the treatment of such infections in animals is a trypanozide based on diminazen powder.
- Other commercially available trypanozides are also only available in powder form.
- the powdered form of the medicament is extremely disadvantageous, since the powdered preparations cannot be added to the feed and they therefore have to be mixed with water in order to prepare an injection solution. It is not possible to prepare a sterile solution from the powdery preparations, since the active substances crystallize out of the solution after a short time, so that the effectiveness of the preparation is quickly lost. Such solutions are therefore not adequately storable and transportable.
- the injection solution must therefore be prepared shortly before the injection, but this is very dangerous due to the generally available water, since it can generally contain bacteria, viruses and germs which cause additional infections in the animals, so that the animals are very heavily burdened by an additional infection.
- a complete solution of the solids is not achieved, so that the solution for injection has a poor effectiveness.
- the currently known powdery trypanozides thus represent a risk of additional infections or contamination, at the same time that There is a risk of underdosing of the therapeutic agent, so that the chemotherapy may have to be repeated, which naturally increases the risk potential for infections or the like.
- aqueous solutions of diminazene diacetate which contain castor oil as a solubilizer.
- the invention is therefore based on the object of providing a solution of a pharmaceutical preparation of the type mentioned at the outset which is stable even at high temperatures.
- the invention provides to create a pharmaceutical preparation with trypanozid properties in the form of an aqueous solution which contains the following substances: - Diminazene di-aceturate
- Diminazene diacetate and pentamidine are trypanoicidal active ingredients which have a different spectrum of activity and thus complement one another in their action, so that almost all types of blood parasites are detected. In addition, resistances are advantageously avoided by the combination.
- the poor water solubility of diminazene diacetate is compensated for by the combination of the two trypanozidic active substances according to the invention, since pentamidine, which is water soluble, acts as a solubilizer.
- the phenazone also brings about better solubility of the diminazene di-aceturate, in addition to its action as an analgesic, which advantageously alleviates pain and fever conditions in the animals which are caused by the injection or the infection.
- Glycerin and the water-soluble cellulose ether serve as emulsifiers.
- a stable aqueous solution can be obtained according to the combination of all of the aforementioned substances.
- the stability of the preparation according to the invention is advantageously so great that it can also be heated to 70 ° C. over a long period of time without any signs of decomposition occurring.
- Methyl-cellulose is preferably used as the water-soluble cellulose ether, although other cellulose ethers, such as, for. B. hydroxy-ethyl cellulose or hydroxypropyl cellulose or their mixed forms are suitable.
- the water used is preferably water which is physiologically, ie. H. in terms of pH and osmolality.
- the water is pH neutral and isotonic. It also has a saline content of 0.9 + 0.3%.
- aqueous solution is obtained as a preparation which can be stored without any problems since the active ingredient cannot crystallize out. In addition, there is no risk of an additional infection since it can be produced under sterile conditions.
- Babesiosis (Babesia bigemina, Babesia motasi, Babesia canis and other Babesia) Theileria annulata.
- the preparation according to the invention is combined with a further antipyretic substance and / or a pain reliever.
- a further antipyretic substance and / or a pain reliever.
- Lidocaine, procaine or their derivatives are preferably used. If necessary, acetylsalicylic acid can also be used as a fever and pain reliever.
- the preparation according to the invention contains isometadium hydrochloride from the group of the phenathridines as a further biocidal active ingredient.
- Methyl cellulose physiologically adjusted water 66.5 vol.-3
- composition in% by weight of the active ingredients is preferably:
- Methyl cellulose 1.6% physiologically adjusted water 78.4%.
- the preparation according to the invention has the advantage that, based on the volume, the active substance content can be doubled compared to the prior art.
- a particular advantage is that a single injection, which is necessary for chemotherapy, also provides three-month protection against reinfections.
- a preferred embodiment of the pharmaceutical preparation is produced by the biocidal active ingredients, the intended activity-reducing agents.
- water Emulsifier mixture can be mixed.
- the emulsifier / water mixture which is composed of glycerol 20% by volume, methyl cellulose 1.6% by volume and physiological water 78.4% by volume, is then added to the active substances.
- the ready-to-use preparation can be filled sterile filtered.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995130708 DE19530708C2 (en) | 1995-08-21 | 1995-08-21 | Pharmaceutical preparation with trypanocidal properties |
DE19530708 | 1995-08-21 | ||
PCT/EP1996/003657 WO1997006769A2 (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical composition with trypanocidal properties |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0845983A2 true EP0845983A2 (en) | 1998-06-10 |
Family
ID=7769997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96929285A Ceased EP0845983A2 (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical composition with trypanocidal properties |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0845983A2 (en) |
AP (1) | AP827A (en) |
AU (1) | AU6875096A (en) |
DE (1) | DE19530708C2 (en) |
EA (1) | EA199800218A1 (en) |
OA (1) | OA10665A (en) |
WO (1) | WO1997006769A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE29618094U1 (en) * | 1996-10-18 | 1998-02-12 | Bourdichon Alain Jaques | Pharmaceutical preparation |
DE19853937A1 (en) * | 1998-11-24 | 2000-05-25 | Chambord Ltd | Composition useful for treating e.g. malaria, babesiosis and trypanosomiasis comprises diminazene diaceturate and procaine |
DE10325672A1 (en) * | 2003-06-03 | 2004-12-23 | Tropmed Gmbh | Pharmaceutical preparation for the treatment of tropical parasitic diseases |
CN105168121A (en) * | 2015-08-28 | 2015-12-23 | 重庆布尔动物药业有限公司 | Diminazene compound for veterinary use and preparation method of diminazene compound |
RU2638444C1 (en) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Method of increasing medical efficiency for cattle pyroplasmosis with neozidin-m in association with laserpuncture |
RU2638433C1 (en) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Method for increast of therapeutic efficiency of diminasin-70 in case of cattle pyroplasmosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4309415C2 (en) * | 1993-03-19 | 1996-11-07 | Alain Jaques Bourdichon | Pharmaceutical preparation |
-
1995
- 1995-08-21 DE DE1995130708 patent/DE19530708C2/en not_active Expired - Fee Related
-
1996
- 1996-08-20 AU AU68750/96A patent/AU6875096A/en not_active Abandoned
- 1996-08-20 EA EA199800218A patent/EA199800218A1/en unknown
- 1996-08-20 WO PCT/EP1996/003657 patent/WO1997006769A2/en not_active Application Discontinuation
- 1996-08-20 AP APAP/P/1998/001196A patent/AP827A/en active
- 1996-08-20 EP EP96929285A patent/EP0845983A2/en not_active Ceased
-
1998
- 1998-02-20 OA OA9800022A patent/OA10665A/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9706769A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO1997006769A3 (en) | 1997-05-09 |
OA10665A (en) | 2002-09-25 |
WO1997006769A2 (en) | 1997-02-27 |
DE19530708C2 (en) | 1999-01-07 |
DE19530708A1 (en) | 1997-02-27 |
AP9801196A0 (en) | 1998-03-31 |
AP827A (en) | 2000-04-28 |
AU6875096A (en) | 1997-03-12 |
EA199800218A1 (en) | 1998-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19782320B4 (en) | Insecticide combination against fleas and ticks of mammals, especially dogs and cats | |
DE19781981B3 (en) | New pesticide combination | |
EP0117888B2 (en) | Liquid preparations of dihydropyridines, process for their preparation and their use in combating medical disorders | |
DE3612538C2 (en) | ||
DE69818093T2 (en) | LONG-TERM, INJECTABLE, FORMULATIONS CONTAINING RICINO OIL | |
DE60310377T2 (en) | A LONG-TERM, PARASITO-DESOLDERING PREPARATION CONTAINING A SALICYLANILIDE COMPOUND, A POLYMONIC COMPOUND, AND AT LEAST ONE MORE PARASITO-DESOLDERING COMPOUND | |
DE602005002495T2 (en) | Injectable formulation with sodium diclofenac, beta-cyclodextrin and a polysorbate | |
DE69923471T2 (en) | INJECTABLE PROPOFOL FORMULATIONS | |
EP0240829A2 (en) | Carcinostatic agent | |
DE69917248T2 (en) | TOPICAL ANTISEPTIC COMPOSITIONS AND METHOD | |
EP0845983A2 (en) | Pharmaceutical composition with trypanocidal properties | |
DE19780396B3 (en) | Directly applied to the skin solution for parasitism in cattle and sheep | |
DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
DE19726871C1 (en) | Synergistic compositions for the selective control of tumor tissue | |
EP1833499B1 (en) | Homeopathic agent for the prophylaxis of diseases caused by parasites | |
EP2136816B1 (en) | Oleyl phosphocholine | |
WO1996030003A1 (en) | Medicaments for the selective treatment of tumour tissues | |
DE69910738T2 (en) | FUNGICIDAL COMPOSITION CONTAINING A N-BENZOYL-N'-PHENYL UREA DERIVATIVE | |
DE60315597T2 (en) | HALOACETAMIDOBENZOIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC ILLNESSES | |
DE4309415C2 (en) | Pharmaceutical preparation | |
EP3275430A1 (en) | Curcumin solution for intravenous infusion | |
WO1996012504A1 (en) | Oil-in-water formulation for topical application | |
DE2314387C3 (en) | Medicines to treat malignant neoplasms | |
DE2150921C2 (en) | Chemotherapeutically effective preparations containing two active substances | |
DE3030314A1 (en) | SULPHONAMIDE-BASED MEDICINAL PRODUCTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980223 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE DE FR GB IE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 980223 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ATAROST ALLGEM. TIERARZNEIMITTELFABRIK DR. ULRICH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BOURDICHON, ALAIN JACQUES |
|
17Q | First examination report despatched |
Effective date: 20010629 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/655 A, 7A 61K 31/155 B, 7A 61K 31/245 B, 7A 61K 47/38 B, 7A 61K 47/26 B, 7A 61K 31/655 J, 7A 61K 31:155 J, 7A 61K 31:245 J |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20021118 |